miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer

被引：70

作者：

Tan, Hong ^{[1
,2
]}

He, Qingnan ^{[3
]}

Gong, Guanhui ^{[2
]}

Wang, Yixuan ^{[1
,2
]}

Li, Juanni ^{[1
,2
]}

Wang, Junpu ^{[1
,2
]}

Zhu, Ding ^{[1
,2
]}

Wu, Xiaoying ^{[1
,2
]}

机构：

[1] Cent S Univ, Dept Pathol, Sch Basic Med Sci, Changsha 410013, Hunan, Peoples R China

[2] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China

[3] Cent S Univ, Childrens Med Ctr, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2016年 / 48卷 / 01期

基金：

中国国家自然科学基金;

关键词：

miR-382; ovarian cancer; receptor tyrosine kinase orphan receptor 1; epithelial-mesenchymal transition; migration; invasion; EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNAS; DIAGNOSIS; PROGNOSIS; METASTASIS; CARCINOMA; MIRNAS;

D O I：

10.3892/ijo.2015.3241

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Increasing evidence suggests that microRNAs (miRNAs) play a critical role in tumorigenesis. Decreased expression of miR-382 has been observed in various types of cancers. However, the biological function of miRNA-382 in ovarian cancer is still largely unknown. Here, we found miR-382 was downregulated in human ovarian cancer tissues and cell lines. miR-382 inhibited ovarian cancer cell proliferation, migration, invasion and the epithelial-mesenchymal transition (EMT). Furthermore, we identified receptor tyrosine kinase orphan receptor 1 (ROR1) as a target of miR-382, and miR-382 rescued the promotion effect of ROR1 on migration, invasion and EMT process in SKOV3 and COV434 cells. Collectively, these findings revealed that miR-382 inhibits migration and invision by targeting ROR1 through regulating EMT in ovarian cancer, and might serve as a tumor suppressor in ovarian cancer.

引用

页码：181 / 190

页数：10

共 30 条

[1]

Böcker W, 2002, VERH DEUT G, V86, P116

[2] Identification of miR-187 and miR-182 as Biomarkers of Early Diagnosis and Prognosis in Patients with Prostate Cancer Treated with Radical Prostatectomy [J].

Casanova-Salas, Irene ;

Rubio-Briones, Jose ;

Calatrava, Ana ;

Mancarella, Caterina ;

Masia, Esther ;

Casanova, Juan ;

Fernandez-Serra, Antonio ;

Rubio, Luis ;

Ramirez-Backhaus, Miguel ;

Arminan, Ana ;

Dominguez-Escrig, Jose ;

Martinez, Francisco ;

Garcia-Casado, Zaida ;

Scotlandi, Katia ;

Vicent, Maria J. ;

Antonio Lopez-Guerrero, Jose .

JOURNAL OF UROLOGY, 2014, 192 (01) :252-259

[3] Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis [J].

Cui, Bing ;

Zhang, Suping ;

Chen, Liguang ;

Yu, Jianqiang ;

Widhopf, George F., II ;

Fecteau, Jessie-F. ;

Rassenti, Laura Z. ;

Kipps, Thomas J. .

CANCER RESEARCH, 2013, 73 (12) :3649-3660

[4] MicroRNAs in ovarian carcinomas [J].

Dahiya, Neetu ;

Morin, Patrice J. .

[5] Roles for MicroRNAs in Conferring Robustness to Biological Processes [J].

Ebert, Margaret S. ;

Sharp, Phillip A. .

CELL, 2012, 149 (03) :515-524

[6]

Goff BA, 2000, CANCER, V89, P2068, DOI 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO

[7]

2-Z

[8] The Role of miRNA in Haematological Malignancy [J].

Gounaris-Shannon, Stephanie ;

Chevassut, Timothy .

BONE MARROW RESEARCH, 2013,

[9] Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy [J].

Gschwind, A ;

Fischer, OM ;

Ullrich, A .

NATURE REVIEWS CANCER, 2004, 4 (05) :361-370

[10] Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target? [J].

Ingles Garces, Alvaro Henrique ;

Fontes Dias, Mariane Sousa ;

Paulino, Eduardo ;

Moreira Ferreira, Carlos Gil ;

de Melo, Andreia Cristina .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (02) :221-234

← 1 2 3 →